In this study, we demonstrated that LukS-PV targeting C5aR1 inhibits HCC cell proliferation by the HDAC7-Wnt/β-catenin axis, suggesting the strong potential of LukS-PV as a therapeutic cancer drug for HCC treatment. Here, HDAC7 is linked to hepatocellular carcinoma.